Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Could α-N-acetylgalactosaminidase Levels Be Associated With the Presence of Psychotic Symptoms in Methamphetamine Use Disorder? A Cross-Sectional Observational Study

NCT07434401 is registered in ClinicalTrials.gov with Elazığ Mental Health and Diseases Hospital as lead sponsor.

NCT NCT07434401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07434401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Could α-N-acetylgalactosaminidase Levels Be Associated With the Presence of Psychotic Symptoms in Methamphetamine Use Disorder? A Cross-Sectional Observational Study
Lead sponsor
Elazığ Mental Health and Diseases Hospital
Phase
Observational
Overall status
Completed
Start date
May 1, 2025
Completion date
August 31, 2025
Enrollment
93 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine use disorder, methamphetamine-induced psychosis